TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39395139

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care services (medication reconciliation, medication review, patient education)
Number of subjects: 193
Study: 39395230

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccination (specific dosage and duration not mentioned)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccination
Number of subjects: 364
Study: 39395231

Group type: EXPERIMENTAL
Intervention: FAP-IL2v 10 mg administered once every 3 weeks (Q3W) or once weekly (QW) for 4 weeks then once every 2 weeks (Q2W) with corresponding atezolizumab regimens.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: FAP-IL2v plus atezolizumab in PD-L1 positive patients.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: FAP-IL2v plus atezolizumab in PD-L1 negative patients.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: FAP-IL2v plus atezolizumab.
Number of subjects: 48
Study: 39395266

Group type: EXPERIMENTAL
Intervention: Fruquintinib monotherapy
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Fruquintinib combined with chemotherapy and/or anti-PD-1 antibodies
Number of subjects: 520

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 520
Study: 39395411

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 plus chemotherapy (combo)
Number of subjects: 349
Study: 39395424

Group type: EXPERIMENTAL
Intervention: Cabotegravir long-acting injectable
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Oral PrEP
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: PEP
Number of subjects: 984

Group type: COMPARATOR
Intervention: Standard-of-care (oral PrEP and PEP)
Number of subjects: 984

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 984
Study: 39395532

Group type: EXPERIMENTAL
Intervention: EHR-integrable, patient-facing family history software platform based on SMART on FHIR standard
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EHR-integrable, patient-facing family history software platform
Number of subjects: 0
Study: 39395531

Group type: EXPERIMENTAL
Intervention: Intensive postpartum BP control - nifedipine initiation at BP ≥140/90 mmHg to maintain BP <140/90 mmHg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Less intensive postpartum BP control - nifedipine initiation at BP ≥150/100 mmHg to maintain BP <150/100 mmHg
Number of subjects: 60
Study: 39395534

Group type: EXPERIMENTAL
Intervention: Active Symptom Monitoring (ASM)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Patient education without Active Symptom Monitoring (ASM)
Number of subjects: 540
Study: 39395566

Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Exclusion (LAAE) with AtriClip during cardiac surgery
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6500
Study: 39395655

Group type: EXPERIMENTAL
Intervention: Garetosmab (anti-activin A antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39395753

Group type: EXPERIMENTAL
Intervention: Quadrivalent recombinant influenza vaccine (RIV4)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Standard-dose inactivated influenza vaccine (IIV4)
Number of subjects: 415
Study: 39395826

Group type: EXPERIMENTAL
Intervention: henagliflozin combined with CSII
Number of subjects: 200
Study: 39395961

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in patients with high remnant cholesterol (HRC)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in patients with normal remnant cholesterol (NRC)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in patients with high triglyceride (HTG)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in patients with normal triglyceride (NTG)
Number of subjects: 1106
Study: 39395964

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sham auricular acupressure (SAA)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional dosage reduction
Number of subjects: 108
Study: 39396187

Group type: EXPERIMENTAL
Intervention: Turkish version of the Visual Function Classification System (VFCS)
Number of subjects: 2
Study: 39396529

Group type: EXPERIMENTAL
Intervention: Denifanstat 50 mg once per day for 52 weeks
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 39396632

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 20
Study: 39396702

Group type: EXPERIMENTAL
Intervention: High-dose DHA supplementation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 39396714

Group type: EXPERIMENTAL
Intervention: Teleprehabilitation program (personalized multimodal teleprehabilitation)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Teleprehabilitation program
Number of subjects: 394
Study: 39396760

Group type: EXPERIMENTAL
Intervention: Complete protein (lean beef)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Complementary protein sources (navy/black beans and whole wheat bread)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Incomplete protein meal (black beans or whole wheat bread at 1 meal)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-protein control meal (5 g protein)
Number of subjects: 9
Study: 39396938

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 lockdown group
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Immediately following the initial lockdown
Number of subjects: 263

Group type: COMPARATOR
Intervention: Pre-COVID-19 lockdown group
Number of subjects: 263
Study: 39396960

Group type: EXPERIMENTAL
Intervention: High body fat variation rate
Number of subjects: 4609

Group type: EXPERIMENTAL
Intervention: High body fat variation rate in participants with BMI > 30
Number of subjects: 4609

Group type: COMPARATOR
Intervention: Low body fat variation rate
Number of subjects: 4609
Study: 39396984

Group type: EXPERIMENTAL
Intervention: Function-based preventive intervention with feedback and lifestyle counselling (n=15)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group receiving feedback only from standard medical examination (n=12)
Number of subjects: 27
Study: 39396987

Group type: EXPERIMENTAL
Intervention: Celiac plexus block (anesthetic and steroid combination injected into the celiac plexus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham intervention (saline injected into the gastric lumen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celiac plexus block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 0
Study: 39396991

Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioral Therapy (iCBT) with planned feedback
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioral Therapy (iCBT) with on-demand feedback
Number of subjects: 168

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 168
Study: 39397156

Group type: EXPERIMENTAL
Intervention: Exclusive mother's own milk (MOM), N=55 (35%)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Donor human milk (DHM) ± MOM, N=52 (33%)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Preterm formula ± MOM, N=51 (32%)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cumulative intake >150 ml/kg MOM ± DHM within 7-10 days PNA
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Low intestinal permeability (IP)
Number of subjects: 158
Study: 39397221

Group type: EXPERIMENTAL
Intervention: Glycated haemoglobin (HbA1c)
Number of subjects: 247
Study: 39397266

Group type: EXPERIMENTAL
Intervention: Primary PDD-TURBT and omitting Re-TURBT
Number of subjects: 327

Group type: COMPARATOR
Intervention: Standard of care (SoC) comprising primary white-light (WL) TURBT followed by second WL Re-TURBT
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 327
Study: 39397363

Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Best Medical Management (BMT)
Number of subjects: 127
Study: 39397784

Group type: EXPERIMENTAL
Intervention: Prime-2-CoV_Beta vaccine (orf virus-based multi-antigen COVID-19 vaccine)
Number of subjects: 0
Study: 39398317

Group type: EXPERIMENTAL
Intervention: Anti-IgE therapy (omalizumab)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Anti-IL-5/5R therapy
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Anti-IL-4R therapy
Number of subjects: 578
Study: 39398329

Group type: EXPERIMENTAL
Intervention: Improved adherence to vitamin D and calcium supplementation
Number of subjects: 40
Study: 39398493

Group type: EXPERIMENTAL
Intervention: Consolidative stereotactic radiotherapy (SRT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: EGFR-TKI + SRT
Number of subjects: 61

Group type: COMPARATOR
Intervention: EGFR-TKI
Number of subjects: 61
Study: 39399024

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) counseling sessions
Number of subjects: 44
Study: 39399034

Group type: EXPERIMENTAL
Intervention: Increased exposure to mother's speech (T-group: n=21) - 10-minute audio recordings of mothers reading a children's story two times/hour between 10pm-6am, increasing speech exposure by 2.67 hours/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Routine exposure to mother's speech (C-group: n=25)
Number of subjects: 46
Study: 39399572

Group type: EXPERIMENTAL
Intervention: Qualifying prodrome events identified by participants
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Common prodromal symptoms
Number of subjects: 920
Study: 39399678

Group type: EXPERIMENTAL
Intervention: Behavioral HIV preventive intervention for substance using cis and trans gay and bisexual men who have sex with men (GBMSM)
Number of subjects: 68
Study: 39399770

Group type: EXPERIMENTAL
Intervention: Preoperative subacromial injection of bupivacaine and epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preoperative subacromial injection of bupivacaine
Number of subjects: 60
Study: 39399879

Group type: EXPERIMENTAL
Intervention: TV-46000 once monthly (q1m)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TV-46000 once every 2 months (q2m)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39400005

Group type: EXPERIMENTAL
Intervention: Comprehensive remote monitoring (RM) including a monthly symptom questionnaire and notifications for biventricular pacing, premature ventricular contraction, atrial arrhythmias
Number of subjects: 652

Group type: COMPARATOR
Intervention: Standard daily remote monitoring (control group)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Comprehensive remote monitoring (RM)
Number of subjects: 652
Study: 39400109

Group type: EXPERIMENTAL
Intervention: Interleukin 6 (IL6) inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Janus kinase (JAK) inhibitors (upadacitinib at 15 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab (an IL17 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 0
Study: 39400233

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Three-dimensional liver model
Number of subjects: 202
Study: 39400265

Group type: EXPERIMENTAL
Intervention: Herbal formulation, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39400386

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study: 39400388

Group type: EXPERIMENTAL
Intervention: ATRA combined with decitabine (DEC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DEC + ATRA
Number of subjects: 0
Study: 39400529

Group type: EXPERIMENTAL
Intervention: Cention N (CN) restorations
Number of subjects: 25

Group type: COMPARATOR
Intervention: Resin-modified glass ionomer cement (RM-GIC) restorations
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cention N + adhesive system
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cention N + retentive groove
Number of subjects: 25
Study: 39400535

Group type: EXPERIMENTAL
Intervention: Tailored 3- to 5-day exercise programme (n=64)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual hospital care (control, n=66)
Number of subjects: 130
Study: 39400653

Group type: EXPERIMENTAL
Intervention: Aromatherapy group (inhaled Lavender essential oil)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo group (distilled water)
Number of subjects: 100
Study: 39400721

Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC) implemented from July to November.
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control arm (no SMC).
Number of subjects: 166
Study: 39400778

Group type: EXPERIMENTAL
Intervention: Interval group using Bot Fit
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Power group using Bot Fit
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group exercising without Bot Fit
Number of subjects: 45
Study: 39401051

Group type: EXPERIMENTAL
Intervention: Free SDC (Summer Day Camp) every weekday for 8 to 10 weeks
Number of subjects: 422

Group type: COMPARATOR
Intervention: Summer as usual (control)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Free SDC (Summer Day Camp) attendance
Number of subjects: 422

Group type: COMPARATOR
Intervention: No attendance to summer programming
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Every weekday attendance to summer programming
Number of subjects: 422
Study: 39401188

Group type: EXPERIMENTAL
Intervention: 9 sets of 4 repetitions (33% intensity of effort) with 45 s of inter-set recovery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6 sets of 6 repetitions (50% intensity of effort) with 72 s of inter-set recovery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4 sets of 9 repetitions (75% intensity of effort) with 120 s of inter-set recovery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 60
Study: 39401208

Group type: EXPERIMENTAL
Intervention: MAP target of 65 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MAP target of 75 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MAP target of 85 mmHg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recommended MAP target of 65 mmHg
Number of subjects: 0
Study: 39401332

Group type: EXPERIMENTAL
Intervention: Intranasal transplantation of ProtheraCytes
Number of subjects: 0
Study: 39401503

Group type: EXPERIMENTAL
Intervention: EP-104IAR (25 mg intra-articular injection)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Vehicle Control
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: EP-104IAR
Number of subjects: 318
Study: 39401504

Group type: EXPERIMENTAL
Intervention: Iron supplementation (ferrous sulphate 12.5 mg for 6-23 months; 30.0 mg for 24 months and older)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Iron supplementation (ferrous sulphate)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 39401872

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 521
Study: 39402005

Group type: EXPERIMENTAL
Intervention: Renal-artery stenting
Number of subjects: 906

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 906
Study: 39402027

Group type: EXPERIMENTAL
Intervention: Low dose peri-operative dexamethasone followed by pre-operative stereotactic radiosurgery (pSRS)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High dose peri-operative dexamethasone followed by pre-operative stereotactic radiosurgery (pSRS)
Number of subjects: 26
Study: 39402032

Group type: EXPERIMENTAL
Intervention: Tebentafusp treatment
Number of subjects: 69
Study: 39402039

Group type: EXPERIMENTAL
Intervention: Pyroglutamated apelin-13
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 39402448

Group type: EXPERIMENTAL
Intervention: IV difelikefalin (3.0 mcg/kg) in NDD subjects with mild renal impairment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: IV difelikefalin (3.0 mcg/kg) in NDD subjects with moderate or severe renal impairment
Number of subjects: 55

Group type: COMPARATOR
Intervention: IV difelikefalin (0.5, 1.0, or 2.5 mcg/kg) in ESRD subjects undergoing HD
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: IV difelikefalin (3 times per week following dialysis) in ESRD subjects
Number of subjects: 55
Study: 39402517

Group type: EXPERIMENTAL
Intervention: PE+ therapy
Number of subjects: 19
Study: 39402559

Group type: EXPERIMENTAL
Intervention: Conventional tissue clips (CG-TAD)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CNSI lymph node marking (CN-LNM)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Peritumoral CNSI mapping (PCN-MAP)
Number of subjects: 126

Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 126
Study: 39402581

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 1002
Study: 39402603

Group type: EXPERIMENTAL
Intervention: SNP-630
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: SNP-630-MS
Number of subjects: 35
Study: 39402675

Group type: EXPERIMENTAL
Intervention: BI 836880 40 mg, 360 mg, and 720 mg q3w
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 836880 500 mg q3w
Number of subjects: 0
Study: 39402688

Group type: EXPERIMENTAL
Intervention: Implementation strategies including identifying care champions, changing record systems, ongoing training, audit and feedback, and changing physical structure/equipment.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Patient intervention including detection of elevated blood pressure, educational materials, lifestyle modification advice, and medication where needed.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Implementation strategies and patient intervention combined.
Number of subjects: 9
Study: 39402877

Group type: EXPERIMENTAL
Intervention: Whole-food plant-based diet (WPBD) for 16 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CG) instructed not to change their diet
Number of subjects: 36
Study: 39402910

Group type: EXPERIMENTAL
Intervention: MINST + xHyA
Number of subjects: 42

Group type: COMPARATOR
Intervention: MINST alone
Number of subjects: 42
Study: 39403266

Group type: EXPERIMENTAL
Intervention: 20% human serum albumin solution injected via the artery immediately after successful reperfusion (maximum dose 0.60 g/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Endovascular treatment alone (ET cohort)
Number of subjects: 15
Study: 39403397

Group type: EXPERIMENTAL
Intervention: Exposure to whole grain foods over an extended period of time in a free-living situation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 39403556

Group type: EXPERIMENTAL
Intervention: Lenabasum
Number of subjects: 20
Study: 39403561

Group type: EXPERIMENTAL
Intervention: Booster dose of BNT162b2 vaccine
Number of subjects: 68
Study: 39403626

Group type: EXPERIMENTAL
Intervention: Eftilagimod alpha (30 mg subcutaneously every 2 weeks for eight 3-week cycles and then every 3 weeks for up to 54 weeks) plus Pembrolizumab (200 mg intravenously every 3 weeks for up to 105 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Eftilagimod alpha plus Pembrolizumab
Number of subjects: 36
Study: 39403781

Group type: EXPERIMENTAL
Intervention: Topical therapy, methotrexate, adalimumab, secukinumab, or guselkumab (effective treatment achieving PASI 90)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy controls (20 participants)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Circulating biomarkers of endothelial activation (ICAM-1, VCAM-1, E- and P-selectin, GDF-15, TRAIL)
Number of subjects: 80
Study: 39403832

Group type: EXPERIMENTAL
Intervention: Fluorescence confocal microscopy (FCM) using the Histolog® scanner
Number of subjects: 31

Group type: COMPARATOR
Intervention: Paraffin-embedded analysis (PA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Inter-rater agreement among four blinded pathologists
Number of subjects: 31
Study: 39404123

Group type: EXPERIMENTAL
Intervention: Iptacopan 200 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iptacopan
Number of subjects: 0
Study: 39404168

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) plus Care as Usual (CAU)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 139
Study: 39404227

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzalutamide + ADT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzalutamide with other treatments (like docetaxel)
Number of subjects: 0
Study: 39404790

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 30
Study: 39404994

Group type: EXPERIMENTAL
Intervention: Eblasakimab 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eblasakimab 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39405026

Group type: EXPERIMENTAL
Intervention: Radiolabelled exendin
Number of subjects: 14
Study: 39405060

Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 1179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1179
Study: 39405104

Group type: EXPERIMENTAL
Intervention: Family Telehealth Project (telehealth intervention)
Number of subjects: 19
Study: 39405292

Group type: EXPERIMENTAL
Intervention: Local Photobiomodulation
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Vascular Photobiomodulation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo Local Photobiomodulation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo Vascular Photobiomodulation
Number of subjects: 180
Study: 39405373

Group type: EXPERIMENTAL
Intervention: COBRA polyzene F (PzF) stent followed by 14 days of DAPT
Number of subjects: 996

Group type: COMPARATOR
Intervention: FDA-approved new-generation drug-eluting stent followed by 3 or 6 months of DAPT
Number of subjects: 996
Study: 39405605

Group type: EXPERIMENTAL
Intervention: CIETAI combined with PD-1 inhibitor tislelizumab plus oxaliplatin, followed by standard concomitant chemoradiotherapy (capecitabine and 50.4 Gy radiation). Intravenous tislelizumab was administered for an additional two cycles.
Number of subjects: 38